Novartis Gene Therapy Could Be Cost-Effective Up to $1.5 Million

Bookmark
(Bloomberg) -- Novartis AG’s new gene therapy targeting a disease that kills infants would be cost-effective at as much as $1.5 million, according to a U.S. nonprofit that assesses the value of dru...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.